Bexicaserin (INN; developmental code names LP352 and AN352) is a selective serotonin 5-HT2C receptor agonist which is under development for the treatment of seizures in developmental disabilities such as Dravet syndrome and Lennox-Gastaut syndrome.[1][3][2] It is taken by mouth.[2][1]
 | |
| Clinical data | |
|---|---|
| Other names | LP352; LP-352; AN352; AN-352 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2C receptor agonist[1][2] |
| Pharmacokinetic data | |
| Elimination half-life | 5–7 hours[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H19F2N3O |
| Molar mass | 295.334 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug is highly selective for the serotonin 5-HT2C receptor, with negligible affinity for the serotonin 5-HT2A and 5-HT2B receptors.[2] Because it does not activate the serotonin 5-HT2B receptor, bexicaserin is not expected to pose a risk of cardiac valvulopathy, unlike the existing agent fenfluramine.[2]
As of October 2024, bexicaserin is in phase 3 clinical trials for treatment of developmental disabilities.[1][3] It is being developed by Longboard Pharmaceuticals.[1][3]
See also
editReferences
edit- ^ a b c d e f "Bexicaserin - Longboard Pharmaceuticals". AdisInsight. 16 October 2024. Retrieved 29 October 2024.
- ^ a b c d e f Dell'isola GB, Verrotti A, Sciaccaluga M, Roberti R, Parnetti L, Russo E, et al. (June 2024). "Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies". Expert Opinion on Pharmacotherapy. 25 (9): 1121–1130. doi:10.1080/14656566.2024.2373350. PMID 38916481.
- ^ a b c "Delving into the Latest Updates on Bexicaserin with Synapse". Synapse. 28 October 2024. Retrieved 29 October 2024.